Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.

Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, Stratford M, Pearson N, Muschel RJ.

Radiother Oncol. 2014 Apr;111(1):72-80. doi: 10.1016/j.radonc.2014.02.007. Epub 2014 Mar 13.

2.

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, Roué G, Colomer D.

Oncotarget. 2014 Aug 30;5(16):6788-800.

3.

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.

Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM.

J Transl Med. 2011 Aug 11;9:133. doi: 10.1186/1479-5876-9-133.

4.

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.

Breast Cancer Res Treat. 2011 Sep;129(2):387-400. doi: 10.1007/s10549-010-1232-1. Epub 2010 Nov 3.

PMID:
21046231
5.

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.

Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C.

Neuro Oncol. 2010 Dec;12(12):1205-19. doi: 10.1093/neuonc/noq103. Epub 2010 Sep 22.

7.

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.

Lin G, Gai R, Chen Z, Wang Y, Liao S, Dong R, Zhu H, Gu Y, He Q, Yang B.

Eur J Pharmacol. 2014 Apr 15;729:45-53. doi: 10.1016/j.ejphar.2014.02.011. Epub 2014 Feb 20.

PMID:
24561043
8.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.

Br J Cancer. 2014 May 13;110(10):2479-88. doi: 10.1038/bjc.2014.220. Epub 2014 Apr 24.

9.

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.

Gynecol Oncol. 2014 May;133(2):346-52. doi: 10.1016/j.ygyno.2014.02.022. Epub 2014 Feb 19.

PMID:
24561032
10.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
11.

Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.

Doghman M, Lalli E.

Mol Cell Endocrinol. 2012 Nov 25;364(1-2):101-4. doi: 10.1016/j.mce.2012.08.014. Epub 2012 Aug 31.

PMID:
22960230
12.

Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.

Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A.

Cancer Biol Ther. 2012 Sep;13(11):1102-11. doi: 10.4161/cbt.21144. Epub 2012 Aug 16.

13.

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.

Clin Cancer Res. 2010 Dec 15;16(24):6029-39. doi: 10.1158/1078-0432.CCR-10-1490.

14.

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.

Cancer Biol Ther. 2015;16(4):602-9. doi: 10.1080/15384047.2015.1017155. Epub 2015 Apr 14.

15.

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.

Liver Int. 2013 May;33(5):780-93. doi: 10.1111/liv.12126. Epub 2013 Mar 15.

PMID:
23489999
16.

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.

17.

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.

Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-Awar R, Prakesch M, Sun RX, Boutros PC, Venier R, Dickson BC, Gladdy RA.

J Transl Med. 2016 Mar 8;14:67. doi: 10.1186/s12967-016-0814-z.

18.

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013.

19.

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.

PMID:
23832540
20.

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.

Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.

Supplemental Content

Support Center